

# INPLASY

## Risk for HBV reactivation in psoriasis patients treated with cytokine inhibitors: A Systematic Review and Meta-Analysis

INPLASY202360040

doi: 10.37766/inplasy2023.6.0040

Received: 14 June 2023

Published: 14 June 2023

### Corresponding author:

Meng Hsuan Kuo

danms0521@gmail.com

### Author Affiliation:

Dalin Tzu Chi Hospital.

Kuo MH<sup>1</sup>; Tseng, CW<sup>2</sup>; Shao, SC<sup>3</sup>.

### ADMINISTRATIVE INFORMATION

**Support** - None.

**Review Stage at time of this submission** - Completed but not published.

**Conflicts of interest** - None declared.

**INPLASY registration number:** INPLASY202360040

**Amendments** - This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 14 June 2023 and was last updated on 14 June 2023.

### INTRODUCTION

**Review question / Objective** P:psoriasis patients; I:cytokine inhibitors; C:none; O:HBV reactivation, hepatitis.

**Condition being studied** The safety profile of cytokine inhibitors, especially in the newer IL-17 and IL-23 inhibitors in patients with psoriasis and HBV remains uncertain.

### METHODS

**Participant or population** Psoriasis patients with HBV.

**Intervention** Cytokine inhibitors.

**Comparator** None.

**Study designs to be included** Observation study or RCT.

**Eligibility criteria** Studies with case numbers less than 5, those lacking HBV status reporting, and those having overlapping populations with smaller sample sizes were excluded.

**Information sources** PubMed, Embase, Web of Science, and Cochrane Central Register of Controlled Trials.

**Main outcome(s)** HBV reactivation.

**Quality assessment / Risk of bias analysis** Newcastle-Ottawa Scale (NOS).

**Strategy of data synthesis** Random-effects meta-analysis.

---

**Subgroup analysis** Subgroup analyses were performed based on the catalog of cytokine inhibitors (IL-12/23 inhibitor, IL-17 inhibitors, IL-23 inhibitor), risk of bias (moderate and high), study regions (Asian and non-Asian areas), and HBsAb status (HBsAb+ and HBsAb-).

**Sensitivity analysis:** using the one-study removal method.

**Country(ies) involved** Taiwan.

**Keywords** HBV reactivation, cytokine inhibitor, psoriasis.

**Contributions of each author**

Author 1 - Meng Hsuan Kuo.

E mail: danms0521@gmail.com

Author 2 - Chih-Wei Tseng.

Email: cwtseng2@gmail.com

Author 3 - Shih-Chieh Shao.

Email: scshao@cgmh.org.tw